SCHEMBL15413220

SCHEMBL15413220

COc1cc(OC)c(Cl)c(C#Cc2cnc(Nc3c(C)cccc3[N+](=O)[O-])nc2)c1Cl

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 15/20 0.63
▸ FGFR1 P11362 11/20 0.43
▸ FGFR2 P21802 4/20 0.43
▸ FGFR3 P22607 4/20 0.43
▸ RPS6KB2 Q9UBS0 1/20 0.40
▸ CYP1A2 P05177 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18131690 0.89 FGFR4 (0.50) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL23314963 0.87 FGFR4 (0.52) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL15413168 0.83 FGFR4 (0.60) FGFR4FGFR1RPS6KB2CYP3A4CYP2D6
SCHEMBL15434003 0.83 FGFR4 (0.65) FGFR4FGFR1FGFR2FGFR3CYP1A2
SCHEMBL18131714 0.81 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL21756495 0.81 FGFR4 (0.66) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL18131713 0.81 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL21386670 0.78 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3CYP1A2
SCHEMBL15413315 0.77 FGFR4 (1.00) FGFR4FGFR1FGFR2FGFR3CYP1A2
SCHEMBL15413317 0.76 FGFR4 (0.73) FGFR4FGFR1FGFR2FGFR3RPS6KB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109627239-B Inhibitors of fibroblast growth factor receptors 缆图药品公司 2021-10-12 — — CN disclosed
EP-2872491-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2021-05-05 — — EP disclosed
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-02-05 — — US disclosed
US-20180362613-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2018-12-20 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9340514-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2016-05-17 — — US disclosed
US-9126951-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2015-09-08 — — US disclosed
EP-2872491-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR Blueprint Medicines Corporation (US) 2015-05-20 — — EP disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-12-25 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-8802697-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2014-08-12 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2014-07-03 — — US disclosed
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-03-27 — — US disclosed
WO-2014011900-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-01-16 — — WO disclosed
WO-2014011900-A2 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES (US) 2014-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196436-B2 Inhibitors of the fibroblast growth factor receptor FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885
US-20140378481-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885
US-20140088100-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885
US-20140187559-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885
US-20180362613-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback